Introduction: Treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) represents a challenge for clinicians due to the lack of therapeutic options. DLBCL is not a rare disease in Italy. Pixantrone is an aza-anthracenedione, which, when compared to anthracyclines and anthracenediones, has a significantly reduced cardiotoxicity while maintaining good anti-tumor activity. However, the evidence on the use of pixantrone in the context of daily clinical practice is scarce. Methods: We focused on the Italian patient subset of a larger European retrospective study (the PIXA Registry) to assess the efficacy and safety of pixantrone in a real-life DLBCL population. The molecular profile of the disease and its impact on drug efficacy were also assessed. Results: Fifteen heavily pretreated DLBCL patients (13 males and 2 females) underwent treatment with pixantrone for a median of 2 cycles (range 1–6). Eight patients were bcl2 positive, 7 bcl6 positive, and 4 myc positive; 4 patients were diagnosed as double-hit, and 2 as triple-hit DLBCL. The overall response rate was 26.7% with a best response rate of 46.7%. Three patients had grade IV adverse events, which caused drug discontinuation. Four patients had 5 cases of grade III toxicities (1 thrombocytopenia, 1 stomatitis, and 3 neutropenia). One mild cardiac toxicity (sinus tachycardia for which no action was required) was possibly related to the study drug. Conclusion: Our data documented drug efficacy that is satisfactory for this high-risk subset of patients with an acceptable toxicity profile. Results indicate that pixantrone could be a significant treatment option in patients with R/R aggressive DLBCL treated in everyday clinical practice.

1.
Johnson
NA
,
Slack
GW
,
Savage
KJ
,
Connors
JM
,
Ben-Neriah
S
,
Rogic
S
, et al
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
.
J Clin Oncol
.
2012
Oct
;
30
(
28
):
3452
9
.
[PubMed]
0732-183X
2.
Sehn
LH
.
Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma
.
Hematology (Am Soc Hematol Educ Program)
.
2012
;
2012
(
1
):
402
9
.
[PubMed]
1520-4391
3.
Péan
E
,
Flores
B
,
Hudson
I
,
Sjöberg
J
,
Dunder
K
,
Salmonson
T
, et al
The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin’s B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use
.
Oncologist
.
2013
;
18
(
5
):
625
33
.
[PubMed]
1083-7159
4.
Minotti
G
,
Han
H
,
Cattan
V
,
Egorov
A
,
Bertoni
F
.
Pixantrone: novel mode of action and clinical readouts
.
Expert Rev Hematol
.
2018
Jul
;
11
(
7
):
587
96
.
[PubMed]
1747-4086
5.
Eyre
TA
,
Linton
KM
,
Rohman
P
,
Kothari
J
,
Cwynarski
K
,
Ardeshna
K
, et al
Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma
.
Br J Haematol
.
2016
Jun
;
173
(
6
):
896
904
.
[PubMed]
0007-1048
6.
Appio
L
,
Landoni
C
,
La Targia
M
,
Bertolli
V
,
Chiarucci
M
,
Crovetti
G
, et al
Single-agent pixantrone as a bridge to autologous stem cell transplantation in a patient with refractory diffuse large B-cell lymphoma
.
Chemotherapy
.
2017
;
62
(
3
):
187
91
.
[PubMed]
0009-3157
7.
Malaspina
F
,
Pellegrini
C
,
Casadei
B
,
Argnani
L
,
Zinzani
PL
.
Impressive response to pixantrone after allogeneic transplant in a multiple relapsed diffuse large B-cell lymphoma
.
Acta Haematol
.
2017
;
137
(
4
):
191
4
.
[PubMed]
0001-5792
8.
Sancho
JM
,
Navarro
B
,
Soler Campos
JA
,
de Oteyza
JP
,
de Barrenetxea Lekue
C
,
Bregni
M
, et al
Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas
.
Eur J Haematol
.
2020
May
;
104
(
5
):
499
508
.
[PubMed]
0902-4441
9.
AIRTUM Working Group
, Busco S, Buzzoni C, Mallone S, Trama A, Castaing M, et al.
Italian cancer figures—Report 2015: the burden of rare cancers in Italy
.
Epidemiol Prev
.
2016
;
40
(
1
Suppl 2
):
1
120
.1120-9763
10.
Pettengell
R
,
Coiffier
B
,
Narayanan
G
,
de Mendoza
FH
,
Digumarti
R
,
Gomez
H
, et al
Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial
.
Lancet Oncol
.
2012
Jul
;
13
(
7
):
696
706
.
[PubMed]
1470-2045
11.
Pettengell
R
,
Sebban
C
,
Zinzani
PL
,
Derigs
HG
,
Kravchenko
S
,
Singer
JW
, et al
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial
.
Br J Haematol
.
2016
Sep
;
174
(
5
):
692
9
.
[PubMed]
0007-1048
12.
Pettengell
R
,
Coiffier
B
,
Egorov
A
,
Singer
J
,
Sivcheva
L
.
Long-term response and remission with pixantrone in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: post-hoc analysis of the multicenter, open-label, randomized PIX301 trial
.
Clin Drug Investig
.
2018
Jun
;
38
(
6
):
527
33
.
[PubMed]
1173-2563
13.
Broccoli
A
,
Casadei
B
,
Chiappella
A
,
Visco
C
,
Tani
M
,
Cascavilla
N
, et al
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice
.
Oncologist
.
2019
Sep
;
24
(
9
):
1246
52
.
[PubMed]
1083-7159
14.
Levin
A
,
Shah
NN
.
Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas
.
Am J Hematol
.
2019
May
;
94
S1
:
S18
23
.
[PubMed]
0361-8609
15.
Tarantelli
C
,
Gaudio
E
,
Cascione
L
,
Stathis
A
,
Zucca
E
,
Bertoni
F
.
In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas
.
Br J Haematol
.
2019
Jul
;
186
(
1
):
149
52
.
[PubMed]
0007-1048
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.